UK Industry Attacks Government’s ‘Unsustainable’ Repayment Proposals
Questions are being raised about the credibility of the UK’s voluntary and statutory drug pricing schemes because of uncertainty over the payment percentages companies will have to pay in future.
You may also be interested in...
The UK government says it remains committed to the principle of co-creating a positive environment for the development of commercial medicines but there is concern in the life sciences sector over the revelation that companies could be made to pay as much as 26% of their sales in 2023 in rebates to the government.
Faced with the rise in its workload, the UK’s health technology assessment body NICE is exploring ways of tailoring its approach to appraisals according to the type of product under consideration.
An alliance of blood cancer charities has called for multi-indication and combination pricing to be introduced in the UK as part of a future pricing and access deal. The group also requested a transparent and formal way of involving patients as the government and industry negotiate a successor to the Voluntary Scheme for Branded Medicines Pricing and Access, which is due to end in 2023.